Skip to main content
MyDeficiencies

Tiotropium

inhaled long-acting muscarinic antagonist (LAMA)

Also sold as Spiriva HandiHaler, Spiriva Respimat.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Tiotropium has almost no classical depletion machinery. Only a small fraction reaches the circulation (absolute bioavailability 19.5% by dry powder inhalation, 2 to 3% when swallowed), it is cleared mainly as unchanged drug through the kidney (74% unchanged in urine after intravenous dosing, with tubular secretion), it is broken down mostly by non-enzymatic ester cleavage, and in vitro it did not inhibit any of the CYP enzymes tested [1]. The label contains no mention of any vitamin, mineral, anemia or hemoglobin finding [1]. Of the nine mechanism classes screened (absorption interference, enzyme induction, renal wasting, cofactor antagonism, mitochondrial interference, hormonal disturbance, microbiome disruption, changed intake, increased demand), only changed intake (dry mouth, constipation) is present at label level, and no study measured a nutrient outcome behind it.

inhaled long-acting muscarinic antagonist (LAMA) · ATC R03BB04 (WHO ATC/DDD Index [2]) · also sold as Spiriva HandiHaler and Spiriva Respimat · reviewed 2026-10-07. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Tiotropium in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Carnitine: in vitro airway transporter interaction, no systemic measurement

Yellow — Low

See study details

Tiotropium is taken up by the carnitine transporters OCTN1 and OCTN2 and inhibited apical carnitine uptake in airway epithelial models, but no study measured carnitine status in tiotropium users.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null findings: No study measured plasma or urinary carnitine in tiotropium users. The authors of [5] state the work is entirely in vitro and does not measure lung drug levels or systemic carnitine status.
  • At-risk subgroups: Not defined. Moderate renal impairment raises tiotropium exposure 54 to 57% [1], a context flag only.

Regulatory status

Carnitine is not mentioned in the label [1]. The label notes renal clearance exceeding creatinine clearance (tubular secretion) [1].

Direction

Local transporter competition in the airway epithelium; possible systemic retention or loss of carnitine is not shown. Direction for carnitine status: unknown.

Population evidence

None in humans. Rotoli 2020 [5] (Tier B, PLOS One page read through a summarizing tool; the inhibition figure was not visible, so no percentage is available): L-carnitine uptake (1 uM [3H]carnitine, 30 min) with 200 uM of each drug in EpiAirway (n = 3) and Calu-3 cells (n = 4). Glycopyrrolate markedly reduced apical uptake; tiotropium was effective at the apical side "to a lesser extent" and ineffective at the basolateral side, pointing to the apical transporter ATB0,+ (SLC6A14) and not OCTN2. Nakamura 2010 [6] (Tier B, OpenAlex abstract via summarizer): tiotropium was also taken up by HEK293 cells expressing OCTN1 or OCTN2, mainly OCTN2, in the same study that characterized ipratropium transport (no tiotropium kinetic values reported).

Mechanism

Competition at carnitine and organic cation transporters. Whether the systemic tubular secretion of tiotropium involves these transporters, and whether a low circulating exposure could change carnitine handling, is not studied.

Counter-evidence held on record

Counter-evidence and limits The in vitro concentration (200 uM) likely exceeds tissue levels reached by inhaled dosing (an inference; not tested). Systemic exposure is low (bioavailability 19.5% of an inhaled microgram-scale dose) [1]. The authors disagree on substrate versus inhibitor wording. Framing caution Mechanistic curiosity only. Not a deficiency claim, and not a reason to supplement carnitine.

Dietary intake pathway: dry mouth and constipation, nutrient status unmeasured

Yellow — Low

See study details

Dry mouth is the most common adverse reaction to tiotropium and constipation is also reported, which are plausible routes to reduced or altered food intake, but no study measured intake, weight or any nutrient in tiotropium users.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • At-risk subgroups: Older adults (larger dry-mouth increment in the label), people with CrCl under 60 mL/min (higher exposure), people on other anticholinergic drugs (the label advises avoiding co-use), and people with baseline low body weight, a general COPD context and not a tiotropium finding.

Regulatory status

Label (Tier A) documents the adverse reactions: dry mouth 16% versus 3% placebo in 1-year trials, 12% versus 6% versus ipratropium, 5.1% versus 2.7% in the 4-year trial, with larger placebo differences in older age groups (9.0%, 17.1%, 16.2% across age subgroups); constipation 4% versus 2%, 1% versus 1%, and 5.1% versus 3.7% [1]. Dry mouth also appeared in a 13-week trial of 470 patients (9.3% on tiotropium versus 1.6% on placebo) [10]; PubMed listing summary only.

Direction

Changed intake (mechanism class H). This is a drug adverse effect, not a nutrient deficiency (Hard Rule 2); the nutrient consequence, if any, is unmeasured.

Population evidence

No tiotropium study with a nutrient, dietary intake or weight outcome was found. A PubMed search combining tiotropium with body weight, body mass index, nutritional status and malnutrition returned 26 records, of which the first 10 were reviewed at listing level; they used BMI as a covariate or predictor (for example [13], a TIOSPIR and UPLIFT BMI analysis in which BMI was the exposure), none reported a weight change attributed to tiotropium. A mouse study [14] reported weight loss for fluticasone, not tiotropium.

Mechanism

Reduced salivation from muscarinic blockade in the mouth and mild reduced gut motility. Tiotropium is a locally acting inhaled drug with low systemic exposure [1], which limits the expected systemic anticholinergic burden.

Counter-evidence held on record

Counter-evidence and confounding Dry mouth is common in COPD from mouth breathing, oxygen therapy, other medicines, and smoking history. COPD itself drives weight loss. Constipation rates were equal to ipratropium in the ipratropium-controlled trials (1% versus 1%) [1], and the absolute increments are small. Framing caution This is a context flag about adverse reactions, not a nutrient finding. It does not support any supplement recommendation. Oral care and hydration advice belong to the prescriber or pharmacist.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden: reverse direction, in vitro, combination product only

Yellow — Low

See study details

The only mitochondrial data for tiotropium show a combination product reducing smoke-induced loss of mitochondrial membrane potential in a cell line; no study shows mitochondrial injury caused by tiotropium.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null findings: No study of tiotropium alone on mitochondrial function was found; no study reported mitochondrial toxicity.

Regulatory status

No mitochondrial content in the label [1].

Direction

Reverse (protective) in vitro. Not depletion or toxicity.

Population evidence

None in humans. Chen 2020 [4] (Tier B, Springer full-text page read through a summarizing tool): BEAS-2B human bronchial epithelial cells exposed to 5% cigarette smoke extract for 24 hours; pretreatment with tiotropium/olodaterol (olodaterol 10 uM, tiotropium 12.5 or 25 uM, the paper is inconsistent on which) reduced cell death, loss of mitochondrial membrane potential (JC-1 flow cytometry; 34.5% of cells showed the depolarized signal, control value not given in the text) and autophagy, with no significant effect on apoptosis or necrosis. Tiotropium alone was not tested, ROS was not measured, no effect sizes or confidence intervals are reported.

Mechanism

Proposed JNK and autophagy pathway involvement; the causal role of JNK was not confirmed. The concentrations used were micromolar, which is likely far above airway or plasma levels from an 18 mcg inhaled dose (an inference; the paper does not discuss clinical relevance).

Counter-evidence held on record

Counter-evidence and limits A single cell line, one smoke extract preparation, combination treatment, and unpaired t-tests across multiple groups limit the finding. A protective in vitro signal does not show a clinical mitochondrial effect in either direction. Framing caution Not a mitochondrial benefit claim and not a deficiency claim. Do not recommend CoQ10, carnitine or other mitochondrial supplements from this entry.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress: neutral in humans, reverse direction in models

Yellow — Low

See study details

Tiotropium did not change oxidative stress markers in a small human study, and in cat and cell models it reduced smoke-induced oxidative injury, so a pro-oxidant or antioxidant-depleting effect is not supported.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null findings: The human study is itself a null result on all four markers [3].

Regulatory status

No oxidative stress warning or statement in the label [1].

Direction

Neutral (human) and reverse, protective (animal and in vitro). Not depletion.

Population evidence

Ozol 2014 [3] (Tier A, tiotropium-specific, abstract read through OpenAlex reconstruction): 22 stable COPD patients (81% men, mean age 65.4 years) given tiotropium for 4 weeks, before-and-after design with no control group. Exhaled breath condensate nitrotyrosine 4.5 +/- 2.3 to 3.5 +/- 1.9 pg/mL (P = 0.06); 8-isoprostane 7.3 +/- 10.8 to 8.1 +/- 11.7 pg/mL (P = 0.28); interleukin-6 and TNF-alpha also unchanged. The authors conclude tiotropium did not modify inflammatory or oxidative stress markers while symptoms and FEV1 (mean +124.6 mL) improved. Kolahian 2014 [7] (Tier B, abstract via OpenAlex): 15 cats in control, cigarette smoke, and smoke plus tiotropium groups; smoke raised lipid peroxidation in serum, lavage fluid, lung and trachea and lowered antioxidant status, and tiotropium reduced lipid peroxidation and reversed the antioxidant reduction (doses and statistics not recoverable from the record). Albano 2018 [8] (Tier B, PubMed listing summary only, abstract text not retrieved): in 16HBE bronchial cells exposed to cigarette smoke extract, tiotropium alone or with olodaterol lowered several signaling and oxidative markers (ROS, NOX-4, IL-8).

Mechanism

No depleting mechanism. The reduction in smoke-induced markers is likely secondary to reduced muscarinic and inflammatory signaling in the models, not a direct antioxidant action; this was not tested.

Counter-evidence held on record

Counter-evidence and limits The human study had 22 patients, no comparator group and a 4-week window, and one marker approached significance in the favorable direction (P = 0.06). The cat and cell studies used smoke injury models, high or unreported concentrations and no chronic dosing. None measured a systemic antioxidant nutrient such as vitamin C, vitamin E or glutathione in human tiotropium users. Framing caution This is not an antioxidant benefit claim and not a deficiency claim. Do not describe tiotropium as depleting antioxidants or recommend antioxidant supplements from this entry.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No evidence on tiotropium and copper status, ceruloplasmin or copper chelation was retrieved.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition met: no Tier B or C evidence to support yellow, and no circulating claim about tiotropium and copper was found. This is a disclosed gap, not a finding of safety. Kept independent of Iron (Hard Rule 7).

What was searched

PubMed listing for tiotropium AND (iron OR ferritin OR copper OR ceruloplasmin): the page returned a Tie-COPD trial record [17] that matched only on "Iron" in a hospital affiliation, plus a second UID whose record was an unrelated triple therapy versus tiotropium trial [18]; neither mentions copper. DailyMed label full text (about 100,000 of 105,186 characters read via summarizer): no copper content. Drugs.com interaction and monograph pages: no copper content [12].

Channel outcomes

PubMed listing: opened on one phrasing for copper plus iron combined; a separate copper-only phrasing was not run. Web search: unavailable (budget exhausted). Crossref title searches were intermittently rate limited. Europe PMC, Semantic Scholar and eutils: blocked by network policy. Mixed result: a clean zero on the channels that worked, with a thin phrasing range. Tooling-limited as well as a likely genuine gap.

Iron

Not graded — disclosed evidence gap

See study details

No evidence on tiotropium and iron status, absorption or iron-deficiency anemia was retrieved.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition met: no Tier B or C evidence, no circulating claim. Any anemia in COPD is a disease outcome (Hard Rule 2) and is not filed here. Kept independent of Copper and of Oxygen delivery/utilization.

What was searched

Same PubMed listing as Copper (matched only on an affiliation word, so a clean zero for iron); PubMed "tiotropium hemoglobin" (2 records, one unrelated, one a predictor study [11]); "tiotropium anemia" (404, no records); DailyMed label (no iron, anemia or hemoglobin content); Drugs.com pages [12]. Mechanism screen: the label describes no gastric pH effect, chelation or iron-related text [1].

Channel outcomes

As for Copper. Iron-specific phrasings (ferritin, transferrin saturation) were folded into the one combined query. Tooling-limited plus a likely genuine gap.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk: CLASS EXTRAPOLATION from systemic anticholinergics, weak

Yellow — Low

See study details

No study examined tiotropium and the gut microbiome; the only related signal is that anticholinergic use was independently associated with microbiome differences in a Parkinson's disease cohort that did not name its anticholinergics.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null findings: PubMed searches "tiotropium microbiome" and "tiotropium gut microbiota" returned one record, a Chinese medicine trial where tiotropium was background therapy in both arms and the metabolomics were serum-based [16]. No tiotropium-specific gut, oral or lung microbiome study was found.

Regulatory status

No microbiome statement in the label [1].

Direction

Unknown. Class-level association only.

Population evidence

Hill-Burns 2017 [15] (abstract read through OpenAlex reconstruction): 197 Parkinson's disease cases and 130 controls, 16S rRNA stool sequencing, 39 confounders adjusted. Independent microbiome signals were associated with anticholinergic use among patients (P = 0.005), as well as COMT inhibitors (P = 0.0004). The specific anticholinergic agents, effect sizes and taxon directions were not given in the retrieved abstract.

Class cohort test (CLASS EXTRAPOLATION)

Tiotropium was NOT in the cohort: the study was in Parkinson's disease patients and the anticholinergics are unnamed; antiparkinsonian anticholinergics are normally oral systemic agents, which the abstract does not confirm. The shared mechanism would be reduced gut motility from systemic muscarinic blockade, which is far smaller for inhaled tiotropium (bioavailability 19.5% by inhalation, 2 to 3% orally) [1]. Capped at yellow.

Mechanism

Plausible only for systemic anticholinergic exposure through slowed transit. Not demonstrated for tiotropium.

Counter-evidence held on record

Counter-evidence and confounding The Parkinson's disease cohort is heavily confounded by disease, constipation and other medicines. Inhaled use produces a fraction of the systemic exposure. This entry is retained at yellow only because a class-level association exists. Framing caution This is not a claim of dysbiosis from tiotropium. Do not recommend probiotics or fiber changes from this entry.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization: intended bronchodilator effect, reverse direction

Yellow — Low

See study details

In a randomized trial tiotropium improved sleeping oxygen saturation, which reflects the drug's intended effect on airflow; no study shows tiotropium lowering hemoglobin or red-cell mass.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null findings: PubMed searches "tiotropium hemoglobin" returned only the predictor study and an unrelated Russian-language record matched on oxygen saturation; "tiotropium anemia" returned no records (404 on the listing page).

Regulatory status

No anemia, hemoglobin or red-cell statement in the label [1].

Direction

Reverse (improved arterial saturation) and intended pharmacology. Written as a mechanism clarification under Hard Rule 2, not a nutrient-style finding.

Population evidence

Bouloukaki 2016 [9] (Tier A, abstract read through a summarizing tool): randomized open-label trial, 200 patients with mild to moderate COPD (188 completed), tiotropium Respimat versus HandiHaler for 6 months with overnight polysomnography. Both devices improved minimum sleeping SaO2 and time with SaO2 below 90% (TST90) from baseline, and Respimat gave significantly better TST90. Baseline and post values, p values and confidence intervals were not in the retrieved abstract. There was no placebo arm. A 51-patient study [11] lists baseline hemoglobin as a predictor of short-term tiotropium ineffectiveness (reported P = 0.002 for the combined predictors), which is the reverse direction (hemoglobin predicting response, not drug changing hemoglobin); listing summary only.

Mechanism

Bronchodilation and reduced hyperinflation improve ventilation. This is an intended effect. No mechanism by which tiotropium would reduce red-cell mass or oxygen-carrying capacity was found.

Counter-evidence held on record

Counter-evidence and limits Improved saturation is a clinical and physiologic outcome of the drug's indication; it says nothing about nutrient status. COPD itself can cause both polycythemia and anemia of chronic disease, so any hemoglobin change in this population is confounded by indication. Framing caution Do not present this as an oxygen delivery benefit claim or as a deficiency. Anemia is not iron deficiency (Hard Rule 2) and no iron or B12 entry is implied.

ATP production

Not graded — disclosed evidence gap

See study details

No evidence on tiotropium and cellular ATP synthesis or energy output was retrieved.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition met: no Tier B or C source measuring ATP or cellular energy, and no circulating "low energy" claim for tiotropium was found. The mitochondrial membrane potential data are graded under Mitochondrial burden and are not ATP evidence. Kept independent of Mitochondrial burden and Oxygen delivery/utilization (Hard Rule 7). A re-check with respiration and oxidative phosphorylation phrasings is recommended; whole-body energy expenditure data exist but are an outcome of bronchodilation.

What was searched

PubMed listing for tiotropium AND (mitochondria OR mitochondrial OR ATP): 8 records, none measured ATP synthesis. The relevant ones were Chen 2020 [4] (membrane potential, not ATP) and Rotoli 2020 [5] (carnitine uptake); two were drug-list reviews, one a herbal formula study using tiotropium as a mouse comparator. A second phrasing with respiration, oxygen consumption and oxidative phosphorylation terms did not parse (the page returned unrelated trending articles). A third phrasing, "tiotropium bioenergetics", returned 7 records after one rate-limited attempt: again [4] (combination, membrane potential, no ATP measure named), the cat study [7] (inflammation and lipid peroxidation, not energy), a receptor-kinetics minireview and an M3 receptor structure paper (unrelated), the Chinese medicine trial [16] (tiotropium background only), and two human studies of whole-body energy: Cazzola 2010 [19] (28 COPD patients; per the listing summary tiotropium reduced total and active energy expenditure after inhalation, formoterol did not) and a crossover trial [20] (tiotropium improved endurance but not muscular efficiency or resting energy expenditure versus placebo). Both [19] and [20] were read as listing summaries only (the OpenAlex abstract for [19] was null), and they measure whole-body energy expenditure and exercise performance, which follow from reduced work of breathing (the drug's intended effect), not cellular ATP synthesis. They are therefore not filed as ATP evidence.

Channel outcomes

PubMed listing worked on two of three phrasings; web search unavailable; databases other than PubMed listing and OpenAlex single-record lookups were blocked. The respiration and oxidative phosphorylation phrasing was never successfully run, so this is partly tooling-limited; no cellular ATP measure was found in any tiotropium record returned.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Any vitamin, mineral or supplement depletion by tiotropium (B12, vitamin C, vitamin D3, fish oil)

    Where it comes from: Drugs.com lists these four supplements as "most frequently checked interactions" on its tiotropium interaction page, and the Spiriva monograph says to tell the doctor about vitamins and supplements [12]. Tier D. No explicit depletion claim was located for tiotropium on any page opened; antidoteresearch.com had no tiotropium page (404).

    Why it fails: The page gives no interaction text for those supplements, so this is not a claim to rebut but an implied association. The label lists no nutrient interaction [1], the pharmacokinetics show no depletion machinery, and no Tier A, B or C study measured any of these in tiotropium users. Included so readers who met the list elsewhere see why it is not supported.

How the body handles this medication

Metabolism and enzymes
Small extent of metabolism. The ester is cleaved non-enzymatically to N-methylscopine and dithienylglycolic acid, neither of which binds muscarinic receptors. A small fraction is oxidized by CYP2D6 and CYP3A4. At supratherapeutic concentrations tiotropium did not inhibit CYP1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1 or 3A4 in vitro. No CYP induction is described.[1] DailyMed Spiriva HandiHaler label, sec 12.3
Absorption and systemic exposure
Absolute bioavailability 19.5% after dry powder inhalation, 2 to 3% after oral solution, so the swallowed fraction contributes little. Peak plasma about 7 minutes after inhalation. Food is not expected to affect absorption. Plasma protein binding 72%; volume of distribution 32 L/kg after intravenous dosing.[1] sec 12.3
Elimination
74% of an intravenous dose is excreted unchanged in urine. Renal clearance exceeds creatinine clearance, indicating tubular secretion. At steady state after inhalation, urinary excretion was 7% (1.3 mcg) of the dose over 24 hours. Terminal half-life about 25 hours after 5 mcg once daily in COPD patients (the 5 mcg basis is as printed in the retrieved label text); steady state by day 7 with no further accumulation.[1] sec 12.3
Renal impairment
Mild impairment (CrCl 60 to under 90 mL/min) raised AUC0-6,ss by 6 to 23%. Moderate impairment (CrCl 30 to under 60 mL/min) raised it by 54 to 57%, with 15 to 31% higher Cmax,ss. Data for CrCl under 30 mL/min are insufficient. Patients with CrCl under 60 mL/min should be monitored closely for anticholinergic effects. Hepatic impairment was not studied.[1] sec 12.3, 5.6
Anticholinergic adverse effects
Dry mouth is the most common adverse reaction: 16% versus 3% on placebo in 1-year trials, 12% versus 6% against ipratropium, 5.1% versus 2.7% in the 4-year trial; the difference from placebo rose with age. Constipation: 4% versus 2% (1-year placebo-controlled), 1% versus 1% (ipratropium-controlled), 5.1% versus 3.7% (4-year). Use with caution in urinary retention and narrow-angle glaucoma; avoid co-use with other anticholinergics.[1] sec 5.4, 5.5, 6, 7.2
Food, mineral and drug interactions
No food, mineral or supplement interaction is listed. Cimetidine raised tiotropium AUC0-4h by 20% and reduced its renal clearance by 28%; ranitidine had no effect. Inhaled corticosteroids and long-acting beta agonists did not change exposure. The only nutrition-related label text is that the capsule lactose may contain milk proteins.[1] sec 7, 11, 12.3 (label revised 12/2024; page updated November 2025)

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Renal / anticholinergic

    Kidney function

    Exposure rises 54 to 57% in moderate renal impairment (CrCl 30 to under 60 mL/min); label advises close monitoring for anticholinergic effects below CrCl 60 mL/min [1].

  • Symptoms

    Dry mouth and oral health

    Dry mouth is the most common reaction and larger in older patients [1]. Persistent dry mouth is worth raising with the prescriber or dentist; this is not a nutrient finding.

  • Symptoms

    Constipation, urinary retention, eye symptoms

    Constipation, difficulty passing urine (especially with prostatic hyperplasia or bladder-neck obstruction) and eye pain or halos (narrow-angle glaucoma) are label matters [1]. Avoid combining with other anticholinergics.

  • Nutrition context

    Weight and intake

    Tracking weight and appetite is reasonable in COPD generally. No tiotropium-specific nutrient laboratory monitoring is supported by the evidence retrieved.

  • Timing

    Supplement separation

    No food, mineral or supplement separation interval is listed on the label [1]. No supplement dose appears anywhere in this dossier, so no upper-limit comparison was needed.

  • Special populations

    Pregnancy, pediatrics, hepatic

    Not assessed from the label sections read for nutrient purposes. Hepatic impairment was not studied [1]. Renal impairment and older age are the documented sensitivity groups.

Overlap map, to prevent double counting

  • Oxidative stress

    Shares evidence with: Mitochondrial burden

    Note: Both draw on smoke-injury models, but different papers: [7] and [8] for oxidative markers, [4] for membrane potential. [4] and [8] are both bronchial epithelial cell-line studies that include the tiotropium/olodaterol combination. Treat as one mechanistic theme (smoke injury attenuation), not independent confirmations.

  • Mitochondrial burden

    Shares evidence with: ATP production (ungraded)

    Note: The ATP search returned the same mitochondrial records [4]; membrane potential is not ATP. One gap viewed twice.

  • Carnitine

    Shares evidence with: Mitochondrial burden; ATP production

    Note: Carnitine supports mitochondrial fatty acid oxidation, so a hypothetical carnitine effect would be upstream of both. No shared source; no carnitine effect on either is demonstrated. Not double counted.

  • Oxygen delivery/utilization

    Shares evidence with: Iron (ungraded)

    Note: No shared source. Hemoglobin was found only as a baseline predictor [11]. Any anemia would be an outcome and would route through the iron entry.

  • Dietary intake pathway

    Shares evidence with: Gut microbiome risk

    Note: Both involve reduced gut motility from anticholinergic action, but the intake entry rests on the label and the microbiome entry on a separate class study [15]. A microbiome shift is not claimed.

  • ATP production (ungraded)

    Shares evidence with: Oxygen delivery/utilization

    Note: The whole-body energy studies [19][20] and the sleep saturation trial [9] all reflect the intended bronchodilator effect (less work of breathing, better ventilation). They are not ATP evidence and are counted only as context for the oxygen entry.

  • Copper

    Shares evidence with: Iron

    Note: Both ungraded from the same combined PubMed query that matched on an affiliation word. Graded separately per Hard Rule 7.

All references used above
  1. SPIRIVA HANDIHALER (tiotropium bromide) capsule, DailyMed label, Boehringer Ingelheim. — Regulatory label (Tier A). Read through a summarizing fetch tool: about 100,000 of 105,186 characters, covering sections 5, 6, 7, 11 and 12.3. Highlights show "Revised: 12/2024"; page updated November 10, 2025. Used for all PK, adverse reaction and interaction facts.Spiriva Respimat label not separately opened; half-life is quoted as printed in the retrieved text (5 mcg basis).
  2. WHO Collaborating Centre, ATC/DDD Index: tiotropium bromide, R03BB04. — DDD 10 mcg (inhalation powder), 5 mcg (inhalation solution). Reference index.
  3. Ozol D, Karamanli H, Uysal S, Yigitoglu MR, Yildirim Z. Airway inflammation and tiotropium treatment in stable COPD patients. Turk J Med Sci 2014;44(5):804-808. — Before-and-after study, 22 patients, 4 weeks. DOI 10.3906/sag-1303-138. PMID 25539549. Abstract read through an OpenAlex reconstruction and a PubMed listing summary; full text not opened.
  4. Chen CH, Li YR, Lin SH, Chang HH, Chai WH, Chan PC, Lin CH. Tiotropium/olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells. BMC Pharmacol Toxicol 2020;21:74. — In vitro. DOI 10.1186/s40360-020-00451-0. PMID 33129351. Full-text page read through a summarizing tool.Combination product; tiotropium alone not tested.
  5. Rotoli BM, Visigalli R, Barilli A, Ferrari F, Bianchi MG, Di Lascia M, Riccardi B, Puccini P, Dall'Asta V. Functional analysis of OCTN2 and ATB0,+ in normal human airway epithelial cells. PLoS One 2020;15(2):e0228568. — In vitro. DOI 10.1371/journal.pone.0228568. PMID 32027707. Full-text page read through a summarizing tool; figure 7 values not visible.
  6. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells. Mol Pharm 2010;7(1):187-195. — In vitro. DOI 10.1021/mp900206j. PMID 20020740. Abstract read through an OpenAlex lookup via summarizer; the tiotropium statement is secondary to the ipratropium focus.
  7. Kolahian S, Shahbazfar AA, Tayefi-Nasrabadi H, Keyhanmanesh R, Ansarin K, Ghasemi H, Rashidi AH, Gosens R, Hanifeh M. Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation. Exp Lung Res 2014;40(6):272-287. — Animal study, 15 cats. DOI 10.3109/01902148.2014.905657. PMID 24784973. Abstract via OpenAlex reconstruction; doses and statistics not recoverable.
  8. Albano GD, Bonanno A, Moscato M, Anzalone G, Di Sano C, Riccobono L, Wenzel SE, Profita M. Crosstalk between the M3 muscarinic acetylcholine receptor and the beta2-adrenergic receptor in human bronchial epithelial cells after long-term cigarette smoke exposure. Life Sci 2018;192:99-109. — In vitro. DOI 10.1016/j.lfs.2017.11.034. PMID 29175450.Abstract text not retrieved (OpenAlex abstract field null). Findings come from a PubMed listing summary only; the listing title wording differed slightly from the OpenAlex title. Treat as secondary.
  9. Bouloukaki I, Tzanakis N, Mermigkis C, Giannadaki K, Moniaki V, Mauroudi E, Michelakis S, Schiza SE. Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD. Sleep Breath 2016;20(2):605-612. — Randomized open-label trial, 200 patients. DOI 10.1007/s11325-015-1259-y. PMID 26407963. Abstract only, via PubMed listing summary.An OpenAlex lookup for this record timed out. No numeric results were in the retrieved abstract.
  10. Spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000. — RCT, 470 patients (279 tiotropium, 191 placebo); dry mouth 9.3% versus 1.6%. PMID 11083677. Authors not captured. PubMed listing summary only; abstract not opened.
  11. Predictors of short-term LAMA ineffectiveness in treatment naive patients with moderate to severe COPD. Wien Klin Wochenschr 2018. — 51 patients, tiotropium for 3 months. PMID 29322375. PubMed listing summary only.Hemoglobin is a baseline predictor, not an outcome of tiotropium. Not a nutrient measurement.
  12. Drugs.com. Tiotropium drug interactions page and Spiriva monograph (consumer pages). — Tier D. Used only to audit circulating claims. Read through a summarizing tool.
  13. Mortality and exacerbation risk by body mass index in patients with COPD in TIOSPIR and UPLIFT. Ann Am Thorac Soc 2022. — PMID 34406915. PubMed listing summary only. BMI was the exposure; tiotropium was the trial setting.Not a tiotropium weight outcome; cited to show absence of one.
  14. Tiotropium attenuates virus-induced pulmonary inflammation in cigarette smoke-exposed mice. J Pharmacol Exp Ther 2016. — Mouse study. PMID 27016458. PubMed listing summary only; weight loss noted for fluticasone.
  15. Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 2017;32(5):739-749. — Cross-sectional, 197 PD cases and 130 controls. DOI 10.1002/mds.26942. PMID 28195358. Abstract via OpenAlex reconstruction.Tiotropium not in the cohort; anticholinergic agents not named. Tier C.
  16. Multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable COPD. J Tradit Chin Med 2026;46(3):652-665. — RCT, 270 patients. PMID 42365412. PubMed listing summary only.Tiotropium was background therapy in both arms, not the studied exposure. Excluded as evidence.
  17. Tiotropium in early-stage chronic obstructive pulmonary disease (Tie-COPD). 2017. — RCT, 841 patients. PMID 28877027. PubMed listing summary only; journal inferred as NEJM from ISSN and DOI prefix.Matched the copper and iron query only on a hospital affiliation word. No nutrient outcome.
  18. Single-inhaler FF/UMEC/VI triple therapy versus tiotropium monotherapy in COPD. npj Prim Care Respir Med 2021;31:29. — RCT, 800 patients. DOI 10.1038/s41533-021-00241-z. PMID 34035312. OpenAlex abstract.Unrelated to iron or copper; no nutrient outcome.
  19. Cazzola M, Segreti A, Stirpe E, Appodia M, Senis L, Matera MG. Energy expenditure and impact of bronchodilators in COPD patients. Respir Med 2010;104(10):1490-1494. — Human study, 28 COPD patients, tiotropium versus formoterol. DOI 10.1016/j.rmed.2010.04.002. PMID 20471237. PubMed listing summary only; OpenAlex abstract was null.Whole-body energy expenditure, not cellular ATP. Not used as ATP evidence.
  20. Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011. — Crossover trial, tiotropium versus placebo. PMID 21660300. Authors and sample size not captured. PubMed listing summary only.Whole-body and muscle-efficiency outcomes, not cellular ATP. Not used as ATP evidence.